Elebsiran

Elebsiran (VIR-2218) is a siRNA that targets and degrades hepatitis B virus (HBV) and hepatitis D virus (HDV) RNA transcripts. Elebsiran leads to a significant decrease in HBV surface antigen (HBsAg) and a reduction in viral load. Elebsiran binds to the sialic acid-depleted glycoprotein receptor (ASGPR) on the surface of liver cells through the GalNAc ligand, achieving liver-targeted delivery and demonstrating improved liver safety. Elebsiran can be used for the study of chronic HBV/HDV infections[1][2][3].

Product Specifications

CAS Number

[2648009-64-5]

Product Name Alternative

VIR-2218

UNSPSC

12352208

Target

HBV; Small Interfering RNA (siRNA)

Type

Oligonucleotides

Related Pathways

Anti-infection; Epigenetics

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/elebsiran-1.html

Solubility

10 mM in H2O

Smiles

[Elebsiran]

Molecular Formula

C485H658N158F9O294P39S6

Molecular Weight

14976.67

References & Citations

[1]Zhou J, et al. Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection. JHEP Rep. 2025 Mar 22;7 (6) :101400.|[2]Gupta SV, et al. Clinical and Preclinical Single-Dose Pharmacokinetics of VIR-2218, an RNAi Therapeutic Targeting HBV Infection. Drugs R D. 2021 Dec;21 (4) :455-465. |[3]Ji Y, et al. The Impact of Hepatitis B Surface Antigen Reduction via Small Interfering RNA Treatment on Natural and Vaccine (BRII-179) -Induced Hepatitis B Virus-Specific Humoral and Cellular Immune Responses. Gastroenterology. 2025 Jul;169 (1) :136-149.